Your Eczema Drug
May Have Hidden
Your Cancer.
Dupixent (dupilumab) suppresses the same immune pathways that drive both eczema and early-stage cutaneous T-cell lymphoma — a rare cancer that looks almost identical to severe eczema. Studies found Dupixent users develop CTCL at rates up to 30 times higher than users of all other medications combined. The Dupixent label contains no cancer warning. Sanofi and Regeneron face active failure-to-warn lawsuits — and attorneys handling Dupixent lymphoma claims are reviewing cases nationwide.
Litigation Status
No Warning on the Label.
Cancer in the Data.
The Dupixent prescribing label — as of current lawsuits — contains no warning about the risk of cutaneous T-cell lymphoma or any other lymphoma. The FDA's own adverse event database flagged CTCL as a Dupixent safety signal in late 2024. Sanofi and Regeneron had this data. Patients did not.
The FDA's October–December 2024 FAERS quarterly report identified "Dupixent (dupilumab) – Cutaneous T-cell lymphoma" as a potential signal of serious risk requiring formal regulatory evaluation. The agency placed Dupixent on a list of medications with potentially serious risks in March 2025. CTCL still appears nowhere on the Dupixent product label.
Dupixent lymphoma and CTCL lawsuits are active against Sanofi and Regeneron. The first Dupixent wrongful death lawsuit was filed in October 2025 — a Tennessee patient who died of T-cell lymphoma months after starting Dupixent. Plaintiffs and defendants are seeking MDL consolidation of Dupixent cancer cases in federal court.
Attorneys in this network handle Dupixent lawsuit and lymphoma settlement claims on pure contingency. No retainer. No hourly billing. No upfront fees. If no compensation is recovered on your behalf, you owe nothing — period.
"Dupixent can make early lymphoma look like eczema responding to treatment. Patients had no way to know."
Cancers & Legal Theories
What Dupixent Lawsuits
Are Built On
Dupixent lymphoma lawsuits rest on two interconnected failures by Sanofi and Regeneron: first, they did not warn patients that dupilumab was associated with a dramatically elevated CTCL risk; second, they did not warn physicians or patients that the drug's mechanism of action could mask early-stage lymphoma as responding eczema — delaying diagnosis while cancer advanced unchecked. A connected attorney will assess how these theories apply to your situation at no cost.
Dupixent CTCL Lawsuit — Cutaneous T-Cell Lymphoma & Failure to Warn
Cutaneous T-cell lymphoma is a rare non-Hodgkin lymphoma originating in T-lymphocytes that primarily affects the skin — presenting with patches, plaques, or tumors that can closely mimic treatment-resistant eczema. Multiple peer-reviewed studies document a 350% elevated CTCL risk in Dupixent users, and a 2025 pharmacovigilance analysis found CTCL reported approximately 30 times more often for Dupixent than for all other medications combined. The Dupixent label contains no CTCL warning. Lawsuits allege Sanofi and Regeneron possessed this signal from their own adverse event monitoring and failed to disclose it.
Dupixent Masking Lawsuit — Eczema Drug That May Hide Early-Stage Lymphoma
Early mycosis fungoides — the most common CTCL subtype — is clinically indistinguishable from severe atopic dermatitis. Dupixent suppresses IL-4 and IL-13 signaling, which drives inflammation in both eczema and early CTCL. This means the drug can suppress the visible skin manifestations of an undetected lymphoma, creating the appearance of eczema improvement while the cancer progresses beneath the surface. Lawsuits allege Sanofi and Regeneron knew of this masking mechanism and failed to require pre-treatment biopsy evaluation or to warn prescribers to stop and investigate when skin disease followed an atypical clinical course.
Mycosis Fungoides & Sézary Syndrome — Advanced Lymphoma Diagnosis Claims
Mycosis fungoides progresses through distinct clinical stages — patches, plaques, tumors, and ultimately erythrodermic or leukemic disease. Sézary syndrome, the leukemic variant, carries a substantially worse prognosis. Patients who were treated with Dupixent while harboring undetected mycosis fungoides — experiencing apparent improvement of skin symptoms while the disease advanced to a later stage — have delayed-diagnosis claims reflecting both the physical harm of the advanced cancer and the loss of treatment options that earlier detection would have preserved.
Dupixent Peripheral T-Cell Lymphoma Lawsuit — PTCL & Systemic Lymphoma Claims
Beyond cutaneous T-cell lymphoma, Dupixent has been associated with peripheral T-cell lymphoma — an aggressive systemic lymphoma arising in mature T-lymphocytes. A 2025 study found asthma patients treated with dupilumab had a 4.5-fold higher risk of T-cell and NK-cell lymphomas compared to those on standard asthma therapy. A wrongful death lawsuit filed in October 2025 involves a patient who developed PTCL — an aggressive and often fatal cancer — within months of starting Dupixent. PTCL claims carry significant weight given the aggressive clinical course of the disease.
Dupixent Wrongful Death Lawsuit — Fatal Lymphoma Claims Against Sanofi & Regeneron
The first Dupixent wrongful death lawsuit was filed in October 2025 on behalf of a Tennessee woman who died of T-cell lymphoma after beginning Dupixent treatment in June 2024. Her family's complaint alleges Sanofi and Regeneron knew about the lymphoma risk and failed to disclose it to patients or prescribers — and that had the risk been disclosed, she and her physicians would have made different treatment decisions. Wrongful death claims in Dupixent litigation carry the full measure of damages available under applicable state law.
Failure to Warn — No CTCL Warning on Dupixent Label Despite FDA Safety Signal
The failure-to-warn theory is the spine of all Dupixent lymphoma litigation. Sanofi and Regeneron received adverse event reports identifying CTCL in dupilumab users, had access to post-market pharmacovigilance data flagging a disproportionate CTCL signal, and the FDA eventually identified the same signal in 2024 — yet as of the filing of current lawsuits, the Dupixent label contains no warning about lymphoma or CTCL risk. Patients who received no warning about the cancer risk, no instruction to seek dermatopathological evaluation before or during treatment, and no guidance on when to stop and investigate had their autonomy as patients violated by Sanofi and Regeneron's labeling decisions.
Eligibility
Signs Your Situation
May Support a Claim
The core question is whether you used Dupixent as prescribed and were subsequently diagnosed with cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, peripheral T-cell lymphoma, or another lymphoma — or whether your lymphoma diagnosis was delayed because Dupixent masked its symptoms as eczema. A connected attorney makes the final determination at no cost.
You were prescribed Dupixent for eczema, atopic dermatitis, asthma, or another condition and used it for at least one month
Dupixent lymphoma lawsuits involve patients who used dupilumab across all approved indications — including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic conditions. Most CTCL diagnoses in documented cases occurred within the first year of Dupixent use. Duration of use of at least one month is the threshold applied in most current claims evaluations.
You were diagnosed with cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, or peripheral T-cell lymphoma after starting Dupixent
Any of these lymphoma diagnoses arising during or following Dupixent use — confirmed by biopsy, pathology, or hematological workup — is the qualifying injury in Dupixent cancer litigation. The absence of a prior lymphoma or hematological malignancy diagnosis before starting Dupixent is an important qualifying factor that a connected attorney will assess.
Your eczema "improved" on Dupixent but you were later diagnosed with CTCL — the cancer may have been masked
Patients whose skin symptoms appeared to respond to Dupixent, but who were later diagnosed with mycosis fungoides or another CTCL, may have experienced the masking mechanism at the center of these lawsuits — the drug suppressed the visible inflammation of an undetected lymphoma, creating the appearance of eczema treatment success. A connected attorney can assess whether delayed diagnosis is part of your claim.
You were not warned that Dupixent could increase your risk of cancer or that it might mask early lymphoma as eczema
The Dupixent label contains no CTCL or lymphoma warning. If your prescribing physician had no warning to pass along — because Sanofi and Regeneron withheld it from the labeling despite the available safety signal — the failure-to-warn chain runs directly from the manufacturer to you. Lack of disclosure is central to all Dupixent lymphoma claims currently being filed.
A family member died after developing lymphoma following Dupixent use
Dupixent wrongful death lawsuits are being filed on behalf of patients who died of T-cell lymphoma following dupilumab treatment. If a family member received Dupixent, subsequently developed PTCL, CTCL, or another lymphoma, and died from the disease — particularly if the diagnosis came rapidly after starting the drug — a connected attorney can evaluate a wrongful death claim at no cost.
Your lymphoma diagnosis falls within the applicable statute of limitations window
Statutes of limitation for Dupixent lawsuits vary by state — typically two to three years from diagnosis or from when you connected your lymphoma to your Dupixent use. Because many patients received delayed diagnoses due to the masking mechanism, the discovery rule may extend the filing window. A connected attorney can confirm your deadline at no cost.
How It Works
No Upfront Costs.
Your Claim, Fully Handled.
Attorneys in this network manage the complete Dupixent lymphoma lawsuit process — from free evaluation through filing and litigation against Sanofi and Regeneron. Your role is sharing your medical history. Everything else is handled.
Free Confidential Evaluation
A connected attorney reviews your Dupixent use history and your lymphoma or CTCL diagnosis — including the timing of diagnosis relative to your treatment and whether delayed diagnosis may be part of your claim. No cost, no obligation to proceed.
Medical & Prescription Records
Dupixent prescription history, dermatopathology reports, biopsy results, oncology records, treatment documentation, and expert review are gathered to establish both your drug exposure and the full clinical picture of your lymphoma diagnosis — including evidence of delayed diagnosis from masking.
Filing Against Sanofi & Regeneron
Your Dupixent lawsuit is filed against Sanofi and Regeneron under failure-to-warn, negligence, and product liability theories. As MDL consolidation proceeds, your claim will be coordinated with others nationwide — with shared expert discovery and bellwether trial outcomes informing your case.
Settlement or Resolution
Attorneys in this network collect a contingency fee only from your recovery. There is nothing to pay at any stage — no retainer, no hourly billing, no upfront fees of any kind.
From Those Who Filed
Their Words
"My eczema seemed to be doing better on Dupixent. Then a biopsy came back as mycosis fungoides. My oncologist told me the drug had almost certainly been suppressing the visible signs of the cancer. I had no idea that was even possible."
"I was on Dupixent for eight months before my diagnosis. There was nothing on the label about lymphoma — not a word. I asked my dermatologist and she hadn't seen any warning either. Nobody knew. That is not acceptable for a drug this widely prescribed."
"My mother started Dupixent in June and was gone by October. T-cell lymphoma — extremely aggressive, diagnosed too late. She never had a single conversation about cancer risk because none was disclosed. We filed within days of learning about the wrongful death lawsuits."
Common Questions
What You Need to Know
Yes. Dupixent CTCL and lymphoma lawsuits are active against Sanofi and Regeneron. Claims allege the companies failed to warn patients that dupilumab was associated with a dramatically elevated risk of cutaneous T-cell lymphoma and peripheral T-cell lymphoma — and that the drug could mask early-stage CTCL as eczema, delaying life-altering diagnosis. A wrongful death suit was filed in October 2025. MDL consolidation is being pursued. Submit your information for a free evaluation to find out if your situation qualifies.
Multiple peer-reviewed studies document that Dupixent users develop CTCL at substantially elevated rates — up to 350% higher risk compared to patients not treated with the drug, and CTCL reported approximately 30 times more often for Dupixent than for all other medications combined in FDA adverse event data. Researchers have proposed two mechanisms: dupilumab may directly promote T-cell malignancy through IL-4/IL-13 pathway modulation, or it may mask early CTCL as eczema. Causation is not yet legally established, but the statistical association is the foundation of current litigation. A connected attorney can assess whether your diagnosis qualifies.
Early mycosis fungoides — the most common CTCL subtype — looks nearly identical to severe atopic dermatitis on the skin. Dupixent suppresses the same inflammatory pathways active in both conditions, which means it can reduce the visible skin symptoms of an undetected lymphoma — making it appear as if eczema is responding to treatment while the underlying cancer progresses. Lawsuits allege Sanofi and Regeneron knew of this masking risk and failed to warn physicians to rule out CTCL before starting treatment or to stop and investigate when disease followed an atypical course. Find out if your diagnosis was delayed by masking.
Mycosis fungoides is the most common form of cutaneous T-cell lymphoma — a slow-developing skin cancer presenting with patches, plaques, or tumors that can closely mimic severe eczema. Sézary syndrome is an aggressive leukemic variant. Both subtypes appear in Dupixent adverse event reports and studies. Because early mycosis fungoides resembles eczema, patients treated with Dupixent for presumed eczema may have had their lymphoma masked — allowing the disease to progress to later, harder-to-treat stages. A connected attorney can assess your specific diagnosis.
Dupixent CTCL and lymphoma settlement values depend on the type and stage of the cancer at diagnosis, whether diagnosis was delayed by the masking mechanism, treatment costs and long-term health consequences, and in wrongful death cases, the full measure of loss under applicable state law. Because Dupixent lymphoma litigation is still building toward MDL consolidation, global settlement benchmarks have not yet been established. A connected attorney can assess your individual claim during a free, confidential review.
The FDA's October–December 2024 FAERS report identified CTCL as a potential Dupixent safety signal requiring formal evaluation. The FDA placed Dupixent on a list of medications with potentially serious risks in March 2025. As of current lawsuits, no CTCL or lymphoma warning appears on the Dupixent product label. Lawsuits allege Sanofi and Regeneron had access to this signal from their own adverse event monitoring before the FDA acted — and failed to update the label. See if the labeling gap applies to your claim.
Yes. Statutes of limitation for Dupixent lawsuits vary by state — typically two to three years from the date of cancer diagnosis or from when you first connected your lymphoma to your Dupixent use. Because many patients had diagnosis delayed by the masking effect, the discovery rule may apply in your state. MDL consolidation is being pursued, making early filing advisable. Contact a connected attorney today to confirm the deadline in your state.
Sanofi Had the Signal.
Patients Had No Warning.
The evaluation is free. The consultation is confidential. There is no obligation until you choose to move forward.